Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Other/Neoadjuvant Chemotherapy

Neoadjuvant Chemotherapy

30

Pipeline Programs↗

27

Active Trials↗

13

Companies Involved↗

Neoadjuvant Chemotherapy is an emerging landscape with 30 programs across 13 companies. 8 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

57/100

Pipeline Velocity

22/100

Mech. Concentration

18/100

Completion Rate

77/100

Attrition Rate

7/100

Pipeline

Programs by Phase

Preclinical4

Definity

Microvascular Therapeutics, LLC

Narlumosbartmab Plus Doxorubicin、cisplatin、methotrexate、ifosfamide

Peking University People's Hospital

Standard Long-Term Therapy

Shanghai Minimally Invasive Surgery Center

Other Individualized Treatments

Shanghai Minimally Invasive Surgery Center

Phase 1

No programs

Phase 218

Neoadjuvant Gemcitabine Plus Nab-Paclitaxel

Changhai Hospital

PM8002

Biotheus Inc.

SOX/XELOX

Xiangdong Cheng

Nivolumab

Bristol-Myers Squibb

Atezolizumab

Roche

Phase 38

Capecitabine

Engelhard Arzneimittel GmbH & Co.KG

Sintilimab Plus Platinum-Based Chemotherapy

Tang-Du Hospital

FOLFIRINOX or Gemcitabine-Nab-Paclitaxel

Sahlgrenska University Hospital

Nab-Paclitaxel and Carboplatin

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Pembrolizumab

Merck & Co.

Approved

No programs

Analysis

Modality Breakdown

83%

Small molecule

24 of 29 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 29 classified programs, each share of the total. Modality classified for 100% of 30 pipeline programs.

Analysis

Trial Status

72

clinical trials

Completed20 · 28%

Unknown status18 · 25%

Recruiting14 · 19%

Not yet recruiting10 · 14%

Terminated4 · 6%

Active, not recruiting3 · 4%

Other3 · 4%

Clinical Trials

Trial Activity

72 trials

Planed Organ Preservation for Low Rectal Cancer After Neoadjuvant Chemotherapy (OPLAR)

Recruiting·WWest China Hospital·Phase 3·NCT07070622·186 enrolled

Neoadjuvant Chemotherapy for Obstructive Colon cancER First Treated by cOlostomy

Recruiting·UUniversity Hospital, Rouen·Phase 3·NCT06107920·232 enrolled

Neoadjuvant Chemotherapy and Transoral Robotic Surgery for Oropharyngeal Cancer.

Recruiting·—·Phase 2·NCT04277858·60 enrolled

Neoadjuvant Chemotherapy and Retifanlimab in Patients With Selected Sarcomas (TORNADO)

Recruiting·IInstitut Bergonié·Phase 2·NCT04968106·66 enrolled

Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC

Recruiting·SSahlgrenska University Hospital·Phase 3·NCT06714604·432 enrolled

PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples

Recruiting·MMedical College of Wisconsin·Phase 2·NCT04683315·84 enrolled

Narlumosbartmab Combined With Neoadjuvant Chemotherapy in Bone-derived Malignancies With Osteolytic Lesions and Multinucleated Giant Cells

Recruiting·PPeking University People's Hospital·N/A·NCT06302465·60 enrolled

Effect of Neoadjuvant Chemotherapy on MRI Accuracy Before Cystectomy

Recruiting·—·N/A·NCT07202819·76 enrolled

Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07)

Recruiting·FFirst Affiliated Hospital of Zhejiang University·Phase 2·NCT07351487·37 enrolled

Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002)

Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 3·NCT04807673·342 enrolled

Primary Chemoradiation VS. Neoadjuvant Chemotherapy Followed By Surgery As Treatment Strategy For LAVC

Recruiting·TThe Netherlands Cancer Institute·Phase 2·NCT05905315·98 enrolled

Camrelizumab Combined With Neoadjuvant Chemotherapy After Stent Placement for Left-Sided Obstructive Colonic Cancer

Recruiting·—·N/A·NCT05202314·20 enrolled

Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02)

Recruiting·FFirst Affiliated Hospital of Zhejiang University·Phase 2·NCT06682195·35 enrolled

Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)

Recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT07209189·75 enrolled

Clinical Study of Neoadjuvant Chemotherapy and Immunotherapy Combined With Probiotics in Patients With Resectable NSCLC

Active, not recruiting·XXiangya Hospital of Central South University·Phase 2·NCT04699721·60 enrolled

Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)